Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 73

1.

Immunological targets for cancer therapy: new recognition.

Shurin MR.

Immunotargets Ther. 2018 Nov 21;7:83-85. doi: 10.2147/ITT.S191821. eCollection 2018. No abstract available.

2.

Alteration of gene expression profile in CD3+ T-cells after downregulating MALT1.

Wang X, Lu S, Xiao Y, Xu L, Zhou L, Hu J, Li B, Zeng C, Li Y.

Immunotargets Ther. 2018 Nov 20;7:77-81. doi: 10.2147/ITT.S179656. eCollection 2018.

3.

Review of checkpoint immunotherapy for the management of non-small cell lung cancer.

Raju S, Joseph R, Sehgal S.

Immunotargets Ther. 2018 Jul 31;7:63-75. doi: 10.2147/ITT.S125070. eCollection 2018. Review.

4.

Multiple effects of CD40-CD40L axis in immunity against infection and cancer.

Ara A, Ahmed KA, Xiang J.

Immunotargets Ther. 2018 Jun 28;7:55-61. doi: 10.2147/ITT.S163614. eCollection 2018. Review.

5.

Antibody targeting of phosphatidylserine for detection and immunotherapy of cancer.

Zohar DN, Shoenfeld Y.

Immunotargets Ther. 2018 Jun 22;7:51-53. doi: 10.2147/ITT.S169383. eCollection 2018. No abstract available.

6.

Melanoma treatment in review.

Domingues B, Lopes JM, Soares P, Pópulo H.

Immunotargets Ther. 2018 Jun 7;7:35-49. doi: 10.2147/ITT.S134842. eCollection 2018. Review.

7.

William Bradley Coley, MD, and the phenomenon of spontaneous regression.

Vernon LF.

Immunotargets Ther. 2018 Apr 23;7:29-34. doi: 10.2147/ITT.S163924. eCollection 2018. Review.

8.

Oncogenes in immune cells as potential therapeutic targets.

Zakiryanova GK, Wheeler S, Shurin MR.

Immunotargets Ther. 2018 Apr 11;7:21-28. doi: 10.2147/ITT.S150586. eCollection 2018. Review.

9.

Immunotherapy in Merkel cell carcinoma: role of Avelumab.

Palla AR, Doll D.

Immunotargets Ther. 2018 Mar 2;7:15-19. doi: 10.2147/ITT.S135639. eCollection 2018. Review.

10.

Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer.

Belzile O, Huang X, Gong J, Carlson J, Schroit AJ, Brekken RA, Freimark BD.

Immunotargets Ther. 2018 Jan 23;7:1-14. doi: 10.2147/ITT.S134834. eCollection 2018. Review.

11.

The current status of immunobased therapies for metastatic renal-cell carcinoma.

Sathianathen NJ, Krishna S, Anderson JK, Weight CJ, Gupta S, Konety BR, Griffith TS.

Immunotargets Ther. 2017 Dec 5;6:83-93. doi: 10.2147/ITT.S134850. eCollection 2017. Review.

12.
13.

Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events.

Davies M, Duffield EA.

Immunotargets Ther. 2017 Aug 24;6:51-71. doi: 10.2147/ITT.S141577. eCollection 2017. Review.

14.

CD8+ memory T-cell inflation renders compromised CD4+ T-cell-dependent CD8+ T-cell immunity via naïve T-cell anergy.

Xu A, Freywald A, Xie Y, Li Z, Xiang J.

Immunotargets Ther. 2017 Jun 15;6:39-49. doi: 10.2147/ITT.S131662. eCollection 2017.

15.

Targeting innate immunity to downmodulate adaptive immunity and reverse type 1 diabetes.

Itoh A, Ridgway WM.

Immunotargets Ther. 2017 May 19;6:31-38. doi: 10.2147/ITT.S117264. eCollection 2017. Review.

16.

FDA-approved immunosuppressants targeting staphylococcal superantigens: mechanisms and insights.

Krakauer T.

Immunotargets Ther. 2017 May 2;6:17-29. doi: 10.2147/ITT.S125429. eCollection 2017. Review.

17.

Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer.

Scholz M, Yep S, Chancey M, Kelly C, Chau K, Turner J, Lam R, Drake CG.

Immunotargets Ther. 2017 Mar 20;6:11-16. doi: 10.2147/ITT.S122497. eCollection 2017.

18.

First-line treatment of metastatic melanoma: role of nivolumab.

Force J, Salama AK.

Immunotargets Ther. 2017 Feb 13;6:1-10. doi: 10.2147/ITT.S110479. eCollection 2017. Review.

19.

Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies.

Hutter C, Minkov M.

Immunotargets Ther. 2016 Oct 12;5:81-91. eCollection 2016. Review.

20.

Toll-like receptors in the pathogenesis of autoimmune diseases: recent and emerging translational developments.

Duffy L, O'Reilly SC.

Immunotargets Ther. 2016 Aug 22;5:69-80. doi: 10.2147/ITT.S89795. eCollection 2016. Review.

Supplemental Content

Loading ...
Support Center